Literature DB >> 9486515

Prevalence of ovarian endometriosis in epithelial ovarian cancer.

H Jimbo1, H Yoshikawa, T Onda, T Yasugi, A Sakamoto, Y Taketani.   

Abstract

OBJECTIVE: The objective of this study was to examine the occurrence of ovarian endometriosis in epithelial ovarian cancer in Japan.
METHOD: The presence of ovarian endometriosis was determined by reviewing the sections of resected specimens in 172 epithelial ovarian cancers.
RESULTS: The incidence of ovarian endometriosis in ovarian cancer (14.5%) was higher than that in Western countries. The rank order of incidence of endometriosis in each histologic type was clear cell (40.6%)>endometrioid (23.1%)>serous (8.7%)>mucinous (2.9%). The incidence in serous type was higher when compared with that reported in Western countries. The higher incidence of endometriosis in Japan can be explained by a greater proportion of clear cell type, comprising 18.6% of all the cases and a higher incidence of endometriosis in the serous type.
CONCLUSION: The association of ovarian endometriosis with epithelial ovarian cancer was more frequently found in Japan.

Entities:  

Mesh:

Year:  1997        PMID: 9486515     DOI: 10.1016/s0020-7292(97)00238-5

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  23 in total

1.  No evidence of endometriosis within serous and mucinous tumors of the ovary.

Authors:  Tadashi Terada
Journal:  Int J Clin Exp Pathol       Date:  2012-02-12

Review 2.  Tubal origin of ovarian endometriosis and clear cell and endometrioid carcinoma.

Authors:  Yiying Wang; Maggie Mang; Yue Wang; Lijie Wang; Robert Klein; Beihua Kong; Wenxin Zheng
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

3.  Recent Trends in Ovarian Cancer Incidence and Relative Survival in the United States by Race/Ethnicity and Histologic Subtypes.

Authors:  Hyo K Park; Julie J Ruterbusch; Michele L Cote
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-07-27       Impact factor: 4.254

4.  Establishment and characterization of a novel ovarian clear cell carcinoma cell line, TU-OC-2, with loss of ARID1A expression.

Authors:  Seiya Sato; Hiroaki Itamochi; Nao Oumi; Youhei Chiba; Tetsuro Oishi; Muneaki Shimada; Shinya Sato; Jun Chikumi; Michiko Nonaka; Akiko Kudoh; Hiroaki Komatsu; Tasuku Harada; Toru Sugiyama
Journal:  Hum Cell       Date:  2016-03-09       Impact factor: 4.174

5.  Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers.

Authors:  William J Lowery; Joellen M Schildkraut; Liudmila Akushevich; Rex Bentley; Jeffrey R Marks; David Huntsman; Andrew Berchuck
Journal:  Int J Gynecol Cancer       Date:  2012-01       Impact factor: 3.437

6.  Serial analysis of gene expression reveals differential expression between endometriosis and normal endometrium. Possible roles for AXL and SHC1 in the pathogenesis of endometriosis.

Authors:  Hiroshi Honda; Fermin F Barrueto; Jean Gogusev; Dwight D Im; Patrice J Morin
Journal:  Reprod Biol Endocrinol       Date:  2008-12-02       Impact factor: 5.211

7.  Gene methylation profiles as prognostic markers in ovarian clear cell and endometrioid adenocarcinomas.

Authors:  Chi-An Chen; Ying-Cheng Chiang; Ming-Cheng Chang; Yu-Hao Hu; San-Lin You; Yeu-Yao Kevin Cheng; Cheng-Yang Chou; Wen-Fang Cheng
Journal:  Am J Transl Res       Date:  2015-01-15       Impact factor: 4.060

Review 8.  Ovarian cancer in endometriosis: epidemiology, natural history, and clinical diagnosis.

Authors:  Hiroshi Kobayashi
Journal:  Int J Clin Oncol       Date:  2009-10-25       Impact factor: 3.402

9.  Magnetic resonance imaging findings of endometrioid adenocarcinoma of the ovary.

Authors:  Kazuhiro Kitajima; Yasushi Kaji; Yoichiro Kuwata; Kazufumi Imanaka; Ryo Sugihara; Kazuro Sugimura
Journal:  Radiat Med       Date:  2007-08-27

Review 10.  Screening, epidemiology, molecular biology, and treatment strategies for endometriosis-associated ovarian cancer.

Authors:  Hiroshi Kobayashi
Journal:  Reprod Med Biol       Date:  2009-09-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.